Portfolio Update: Second Quarter 2020

During the second quarter, the RMB SMID Cap Fund (the "Fund" or "RMBMX") increased +25.40%, net of fees, compared to a +26.56% increase for the Russell 2500 Index. The end of the longest bull market in history was replaced by the shortest bear market in history! The Russell 2500 bounced back in response to an unprecedented six trillion dollars of fiscal and monetary stimulus.

	Quarter	YTD	1 Year	3 Years	5 Years	10 Years	Since Inception (12/31/2004)
RMBMX	+25.40%	-6.30%	+1.26%	+8.16%	+7.31%	+10.98%	+7.49%
Russell 2500 [®] Index	+26.56%	-11.05%	-4.70%	+4.08%	+5.41%	+11.46%	+7.68%

Performance over one year is annualized. The performance data quoted represents past performance and is not a guarantee of future results. The investment return and principal value of an investment will fluctuate, so that those shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. To obtain performance as of the most recent month end, please call 855-280-6423. The Fund's gross expense ratio is 1.06%.

The Fund's investment advisor, RMB Capital Management, LLC, has adapted a contractual expense limitation agreement for each fund through May 1, 2021 reducing the applicable Fund's operating expenses. This may be continued from year to year thereafter if agreed upon by all parties. In the absence of such waivers and/or reimbursements, the applicable Fund's total return and yield would be lower.

In terms of fiscal stimulus, Congress passed the two trillion dollar Coronavirus Aid, Relief and Economic Security (CARES) Act for families and business hurt by COVID-19. The act provides direct payments of \$1200 to individuals, and \$350 billion in loans that do not have to be paid back to small businesses to cover payroll and rent. The CARES Act also allows for interest on mortgage obligations to be delayed without penalty, debt relief on existing loans, \$500 billion in aid to corporations, and expands coverage of telehealth, for online heath care. In terms of monetary stimulus, the Federal Reserve committed four trillion dollars of monetary support and ramped up lending directly to states, cities, and businesses. It also backstopped the commercial credit market, supporting "riskier bonds" (i.e. bailing out illiquid ETFs and structured credit funds). Six trillion dollars of stimulus ignited a powerful "risk-on" rally, as evidenced by the 435 basis point (bps) decline in credit spreads (BAML), from 1065 to 630. Typically, credit spreads range between 350bps - 550bps during an economic expansion.

As we expected, the risk-on trade drove a "dash for trash," which was a headwind for relative performance, given our higher quality portfolio bias. The Fund increased +25.40%, lagging the benchmark for the quarter, still leading the benchmark by 475 basis points YTD.

Whether this is really a new bull market or just a bear market rally is hard to say. One could argue since the economy was so strong and the recession was self-induced with lock downs, that the economy should bounce back rigorously, as per the "V" shaped recovery. The new bull market camp can point to several economic statistics that suggest a "V" recovery is playing out. Thus, a short recession justifies a short bear market. Indeed, seven out of ten bull market indicators we monitor register as positive. But one could also argue the improvement in several economic statistics is a result of six trillion dollars in stimulus, which cannot be sustained without eventually destroying the value of the U.S. dollar. Gold is the insurance against a dollar collapse, and gold has been hitting new highs recently.

Regardless of whether this is a bear market rally, a new bull market, or whether the economic recovery is likely to be a V, W, L, U, a square root or Nike swoosh, it is clear that change is upon us. This change relates to how and where we work, the increasingly important integration of technology into all parts of the economy, how we socialize, the delivery of healthcare, and the prioritization of faster, more efficient drug discovery. These changes are leading to faster adoption curves for many technology and healthcare businesses, while accelerating the demise of highly leveraged, less competitive businesses in retail, entertainment, restaurants, and travel. Bankruptcies have started to accelerate, despite the massive credit made available by



the Federal Reserve. It is all part of the creative destruction process that drives the economy as businesses and investors reallocate capital to adapt to the changing needs of society.

Contributors and Detractors

The biggest contributors to performance were mostly companies that will likely continue to benefit from faster adoption curves as a result of the COVID Pandemic. West Pharmaceutical Services Inc. (WST, +48.94%) manufactures packaging and delivery systems for biologics and is a natural monopoly designed into FDA approvals. Catalent Inc. (CTLT, +41.22%) is a contract manufacturing organization (CMO) for drugs, exposed to the movement to increased outsourcing due to more stringent FDA regulations and trends toward more specialized drugs with more complex manufacturing processes.

The top detractor was insurance company American Financial Group Inc. (AFG, -8.37%) as insurance companies are being impacted by investor concerns regarding potential business interruption liability claims from closings due to COVID-19. Additionally, insurance companies may find it difficult to grow book value in an interest rate environment expected to offer yields below inflation. The Brink's Co. (BCO, -11.88%), which securely moves cash from businesses to banks and among banks, was also a larger detractor. It has been skillfully consolidating the industry, but investors are concerned that the market is moving toward a cashless society, and many retailers and small businesses will disappear, thus creating a structural headwind for Brinks. Our current thinking is the market is over-reacting to the near term fears and not giving enough credit for longer-term opportunities and Brinks remains a high conviction idea.

RMB SMID Cap Fund SECOND QUARTER 2020 CONTRIBUTION REPORT Ranked by Basis Point Contribution

	Basis Point Contribution	Return
Top Contributors		
West Pharmaceutical Services Inc.	+174	+48.94%
Catalent Inc.	+124	+41.22%
Fair Isaac Corp.	+106	+35.53%
MarketAxess Holdings Inc.	+104	+50.86%
Bio-Techne Corp.	+87	+39.43%
Bottom Detractors		
American Financial Group Inc.	-28	-8.37%
The Brink's Co.	-14	-11.88%
Carlisle Companies Inc.	-9	-4.03%
Graco Inc.	-8	-1.15%
Markel Corp.	-5	-0.51%

The performance presented above is sourced through Factset Research Systems Inc. Past performance is not indicative of future results, and there is a risk of loss of all or part of your investment. The above does not represent all holdings in the Fund. Holdings listed might not have been held for the full period. To obtain a copy of RMB's calculation methodology and a list of all holdings with contribution analysis, please contact your service team. The data provided is supplemental. Please see important disclosures at the end of this document.

Portfolio Activity

As mentioned in last quarter's letter, the COVID-19 shock created both new risks and new opportunities. The Fund is adapting to reflect both. As a reminder, the RMB Research Core Team immediately reviewed current Fund holdings and our watch list companies and grouped them into four buckets: 1) **The Power-Through Bucket**, 2) The **Recover Quick Bucket** 3) **The Recover Slow Bucket**, and 4) **Change Leaders**. And we took action to the benefit of our clients.

While our turnover is typically low, it has been a little higher for the first half of the year, and trading (new buys, sell to zero, trim of existing holdings or top off of existing holdings) has contributed to 358 basis points of excess return year-to-date (i.e. the opportunity cost of not taking any action). Furthermore, the hit rate is 72% (52 out of 72 decisions added value defined by excess return relative to the benchmark). The knowledge inventory was leveraged through a balance of adding to existing holdings and new buys; the latter is a function of having actionable work prepared in advance.

During the quarter, we took advantage of the sudden stock market reversal to "risk on" and sold Seattle Genetics Inc. (SGEN) after a 40% return year-to-date and compressed risk reward profile. Other "growth" holdings we trimmed for valuation reasons include Jack Henry & Associates Inc. (JKHY), Tyler Technologies Inc. (TYL), Teleflex Inc. (TFX), MarketAxess Holdings Inc. (MKTX), Catalent Inc. (CTLT), West Pharmaceutical Services Inc. (WST), Fair Issac Corp. (FICO), and IDEXX Laboratories

RMB SMID Cap Fund



Inc. (IDXX). In addition, we used the upward volatility to sell Wolverine World Wide Inc. (WWW) and Cullen/Frost Bankers Inc. (CFR) as we believe their businesses will be slow to recover. We reinvested much of the sale proceeds into more cyclical businesses that we believe have a chance to recover quickly, including Martin Marietta Materials Inc. (MLM), Visteon Corp. (VC), Steel Dynamics Inc. (STLD), ServisFirst Bancshares Inc. (SFBS), The Brink's Co. (BCO), and Pinnacle Financial Partners Inc. (PNFP).

Our cash position is nearly 5%, and we believe markets will remain volatile and we want to have some dry powder to continue to take advantage of potential market sell-offs related to COVID, economic, and election uncertainties.

Outlook

We are big fans of the letters of Howard Marks from Oaktree, so we will borrow from one of his more recent ones where he reminded investors that, "*The ability to deal intelligently with uncertainty is one of the most important skills*."

In our thirty years of investing, we must admit that this is one of the most uncertain moments in our career. We believe our dual diversification portfolio construction process intelligently handles uncertainty by owning just enough high-quality businesses across all industries and lifecycles to handle big, unpredictable shocks, and still outperform over the long term.

While there is always uncertainty, right now it feels like there is a lot more than our standard run-of-the-mill uncertainty around the economy, interest rates, currency, oil, and the geopolitical landscape. What widens the potential outcomes for multiple asset classes is the magnitude of the amount of government intervention, the magnitude of debt and monetary stimulus applied in such a short period of time. The six trillion dollars in additional government support essentially ushered in a new era of policy recommendations such as MMT (Modern Monetary Theory), which proposes deficits do not matter, "universal basic income", which subscribes that all citizens should receive government assistance for basic living needs, and a break in the independence of the Central Bank, as it directly lent to companies and states and bought public market private assets. We are trying to comprehend what the longer-term implications of these crisis policies might be, understand how "temporary" they might be, and how they might affect systematic risk.

No one can predict how much more government intervention may be forthcoming. The government literally mandated a global recession/depression via the lockdowns. Most recently the government mandated that banks could not pay dividends or buy back shares. How will the government deal with a resurgence of COVID or a new strain? More lockdowns? No lockdowns? Central banks have never provided this much capital to markets in such a short period of time and they have committed to do "whatever it takes" to keep markets functioning, without regard for potential price distortion or financial asset bubbles. This could cause an equity melt-up, or it could end in tears, or it may thread the needle of just enough capital to bridge the economy to the other side. We just don't know. The Fed does not know. President Trump does not know. Joe Biden does not know. Nobody knows. In the near term, it appears there is more government and fed stimulus on the way, which should support equity valuations, but we suspect there may also be some bouts of fear along the way creating more volatility and opportunity for active managers to add value.

Perhaps the biggest unknown that investors will need to pay attention to is the election in less than five months. Executive compensation, corporate tax rates, as well as banking, environmental, and many other business regulations may be set to dramatically change. Our job as stewards of our client's capital is not to judge the politics but to understand what changes to the rules could mean for winners and losers in the competition for capital. As we mentioned before, our distinctive portfolio construction process is meant to handle the significant amount of economic and political uncertainty that awaits investors, as the pandemic and political uncertainties unfold throughout the rest of this year. We suspect elevated uncertainty may lead to greater volatility in the second half of the year and if the market sells off, we will be ready, just like last time.

We will continue to strive to own great businesses, managed by great business managers who allocate capital in ways that create value for clients, employees, communities and ultimately shareholders. We are grateful to be part of the capital allocation process and are excited about the continued opportunities to add value for our clients.

RMB SMID Cap Fund



Thank you for your commitment to the Fund. Should you have any questions regarding your investment, please do not hesitate to reach out to us.

Sincerely,

They film

Chris Faber Portfolio Manager

Juffy 23. Madden

Jeff Madden Portfolio Manager

TOP 10 HOLDINGS AS OF 6/30/20

Company	% of Assets
West Pharmaceutical Services Inc.	3.42%
Fair Isaac Corp.	3.08%
Vail Resorts Inc.	2.67%
Catalent Inc.	2.64%
Copart Inc.	2.57%
Bio-Techne Corp.	2.45%
EastGroup Properties Inc.	2.44%
First Republic Bank	2.44%
Repligen Corp.	2.37%
Alexandria Real Estate Equities Inc.	2.32%

Holdings are subject to change. The above is a list of all securities that composed 26.40% of holdings managed as of 6/30/2020 under the RMB SMID Cap Fund ("Fund") of RMB Capital Management, LLC ("RMB Capital") based on the aggregate dollar value. This list is provided for informational purposes only and may or may not represent the current securities managed. It does not represent all of the securities purchased, sold, or recommended for advisory clients (under the Fund or otherwise) during the calendar quarter ending 6/30/2020. The reader should not assume that investments in the securities identified and discussed were or will be profitable. For a complete list of historical recommendation for the Fund, please contact RMB Investors Trust at 855-280-6423.



The opinions and analyses expressed in this letter are based on RMB Capital Management, LLC's ("RMB Capital") research and professional experience, and are expressed as of the date of our mailing of this letter. Certain information expressed represents an assessment at a specific point in time and is not intended to be a forecast or guarantee of future performance, nor is it intended to speak to any future time periods. RMB Capital makes no warranty or representation, express or implied, nor does RMB Capital accept any liability, with respect to the information and data set forth herein, and RMB Capital specifically disclaims any duty to update any of the information and data contained in this letter. The information and data in this letter does not constitute legal, tax, accounting, investment, or other professional advice. Past performance is not indicative of future results, and there is a risk of loss of all or party of your investment. This information is confidential and may not be reproduced or redistributed to any other part without the permission of RMB Capital.

An investment cannot be made directly in an index. The index data assumes reinvestment of all income and does not bear fees, taxes or transaction costs. The investment strategy and types of securities held by the comparison index may be substantially different from the investment strategy and types of securities held by the comparison index may be substantially different from the investment strategy and types of securities held by the comparison index may be substantially different from the investment strategy and types of securities held by our account. The Russell 2500 Index measures the performance of the 2,500 smallest companies in the Russell 3000 Index. The Russell 3000 Index measures the performance of the 3,000 largest U.S. companies based on total market capitalization. The index does not reflect investment management fees, brokerage commissions, or other expenses associated with investing in equity securities.

Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For complete information about the Fund, including a free prospectus, please contact RMB Investors Trust at 855-280-6423, or visit the website at www.rmbfunds.com. The prospectus contains important information about the funds, including investment objectives, risks, management fees, sales charges, and other expenses, which you should consider carefully before you invest or send money.

All investing involves risk including the possible loss of principal. There can be no assurance that the Fund will achieve its investment objective.

Foreside Fund Services, LLC, Distributor